Liminatus Pharma reduces stockholder quorum requirement from majority to one-third

Liminatus Pharma, Inc.

Board approved bylaw amendment reducing quorum from majority to one-third of voting power.
Amendment effective immediately upon Board adoption on February 27, 2026.
Bylaw amendment to be submitted for stockholder ratification at next annual meeting.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Liminatus Pharma, Inc.: Reduced stockholder meeting quorum requirement from majority to one-third of voting power (effective 2026-02-27).

Change: bylaw amendment
Effective: 2026-02-27

Exact text from the filing

On February 27, 2026, the Board of Directors (the “Board”) of Liminatus Pharma, Inc. (the “Company”) approved an amendment to the Company’s bylaws (the “Bylaws”) to reduce the quorum requirement for meetings of the stockholders from a majority to one-third (1/3) of the voting power of the capital stock of the Company issued and outstanding and entitled to vote (the “Bylaw Amendment”).

View on SEC.gov

40 governance changes filed in the last 30 days. Browse all governance changes →

Liminatus Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-023467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.